Polypeptide promoting vascular endothelial cell growth
It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.
1. An isolated polypeptide encoded by the polynucleotide sequence consisting of SEQ ID NO:1.
2. A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 1 .
3. A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, ischemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 1 .
4. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
5. The isolated polypeptide according to claim 4 , which has angiogenesis activity.
6. The isolated polypeptide according to claim 4 , which has vascular endothelial cell growth activity.
7. A pharmaceutical composition for angiogenesis, which comprises the polypeptide of claim 4 .
8. A pharmaceutical composition for growth of vascular endothelial cells, which comprises the polypeptide of claim 4 .
9. A pharmaceutical composition for the treatment of a disease selected from the group consisting of occlusive arterial disease, arteriosclerosis obliterans, Buerger disease, angina, myocardial infarction, cerebral infarction, isehemic heart disease, and ischemic cerebral disease, which comprises the polypeptide of claim 4 .